Prime Medicine Inc

Prime Medicine, Inc. operates as a biotechnology company. It develops one-time curative genetic therapies, Prime Editors to address the wide spectrum of diseases by deploying its Prime Editing technology. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Prime Medicine Inc. PRME, has set terms for its initial public offering, in which the Massachusetts-based biotechnology company, which utilizes gene-editing technology to develop therapies for a wide spectrum of diseases, looks to raise up $160.2 million. The company said it is offering 8.9 million shares in the IPO, which is expected to priced between $16 and $18 a share.

Prime Medicine sets IPO terms, which could value the biotech at up to $1.7 billion

Prime Medicine has filed to raise $100 million in an IPO, although the final figure may be higher. The firm is developing gene editing treatment candidates for a variety of diseases.

Gene Therapy Biotech Prime Medicine Begins U.S. IPO Effort

News for Prime Medicine Inc Stock (PRME)